Page 3 - இந்தியா தேசிய ஸ்டாக் பரிமாற்றம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

India s Shilpa Medicare can make 100-200m doses of COVID-19 vaccine, says exec

Reuters Published: 07 Apr 2021 02:43 PM BdST Updated: 07 Apr 2021 02:43 PM BdST AstraZeneca vaccine against coronavirus disease (COVID-19) is seen in Laakso hospital in Helsinki, Finland Mar 11, 2021. REUTERS Indian drugmaker Shilpa Medicare Ltd has the capacity to manufacture 100-200 million doses of a protein-based vaccine for COVID-19, a company executive told Reuters on Wednesday. ); } India, the world s largest vaccine producing nation, has been ramping up the production of COVID-19 vaccines and global firms including AstraZeneca, US-based Novavax and Russia s RDIF have signed manufacturing deals with local players. RDIF, in particular, has already announced deals with six Indian companies to make more than half a billion doses of its Sputnik-V vaccine, including major drugmaker Dr Reddy s Laboratories and several smaller firms.

Vinay konajeIndia national stock exchangeNational stock exchangeShilpa biologicalsShilpa medicareFortune indiaவினய் கொனஜேஇந்தியா தேசிய ஸ்டாக் பரிமாற்றம்தேசிய ஸ்டாக் பரிமாற்றம்ஷில்பா உயிரியல்ஷில்பா மருத்துவஅதிர்ஷ்டம் இந்தியா

Exclusive-India s Shilpa Medicare can make 100-200 million doses of COVID-19 vaccine, says exec

3 Min Read BENGALURU (Reuters) -Indian drugmaker Shilpa Medicare Ltd has the capacity to manufacture 100-200 million doses of a protein-based vaccine for COVID-19, a company executive told Reuters on Wednesday. Slideshow ( 2 images ) India, the world’s largest vaccine producing nation, has been ramping up the production of COVID-19 vaccines and global firms including AstraZeneca, U.S.-based Novavax and Russia’s RDIF have signed manufacturing deals with local players. RDIF, in particular, has already announced deals with six Indian companies to make more than half a billion doses of its Sputnik-V vaccine, including major drugmaker Dr Reddy’s Laboratories and several smaller firms.

Shounak dasguptaVinay konajeSachin ravikumarSaumyadeb chakrabartyThomson reuters trust principlesShilpa medicare ltdIndia national stock exchangeNational stock exchangeShilpa biologicalsShilpa medicareFortune indiaThomson reuters trustஷ்ௌுனாக் தாஸ்குப்தாவினய் கொனஜேசச்சின் ரவிகுமார்தாம்சன் ராய்ட்டர்ஸ் நம்பிக்கை ப்ரிந்ஸிபல்ஸ்

India s Shilpa Medicare can make 100-200 million doses of COVID-19 shot, says executive

India s Shilpa Medicare can make 100-200 million doses of COVID-19 shot, says executive
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.

India national stock exchangeNational stock exchangeஇந்தியா தேசிய ஸ்டாக் பரிமாற்றம்தேசிய ஸ்டாக் பரிமாற்றம்

India s Shilpa Medicare can make 100-200 million doses of Covid-19 shot

India s Shilpa Medicare can make 100-200 million doses of Covid-19 shot
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

Shounak dasguptaSachin ravikumarShilpa medicare ltdIndia national stock exchangeNational stock exchangeஷ்ௌுனாக் தாஸ்குப்தாசச்சின் ரவிகுமார்ஷில்பா மருத்துவ லிமிடெட்இந்தியா தேசிய ஸ்டாக் பரிமாற்றம்தேசிய ஸ்டாக் பரிமாற்றம்

India s Shilpa Medicare can make 100-200 mln doses of COVID-19 vaccine, says exec

India s Shilpa Medicare can make 100-200 mln doses of COVID-19 vaccine, says exec
leaderpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from leaderpost.com Daily Mail and Mail on Sunday newspapers.

Vinay konajeShilpa medicare ltdIndia national stock exchangeNational stock exchangeShilpa biologicalsShilpa medicareவினய் கொனஜேஷில்பா மருத்துவ லிமிடெட்இந்தியா தேசிய ஸ்டாக் பரிமாற்றம்தேசிய ஸ்டாக் பரிமாற்றம்ஷில்பா உயிரியல்ஷில்பா மருத்துவ